The factors associated with longitudinal changes in liver stiffness in XXXX with @entity6194 .

@entity1 @entity409 @entity6194
BACKGROUND/AIMS: @entity409 ( @entity409 ) as assessed by transient elastography (TE) can change longitudinally in @entity1 with @entity6194 ( @entity6194 ). The aim of this study was to identify the factors that improve @entity409 . METHODS: Between April 2007 and December 2012, 151 @entity1 with @entity6194 who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 @entity1 were treated with nucleos(t)ide analogues [the antiviral therapy (+) group], while the remaining 55 @entity1 were not [the antiviral therapy (-) group]. The two groups of @entity1 were stratified according to whether they exhibited an improvement or a deterioration in @entity409 during the study period (defined as an @entity409 change of  <=0 or >0 kPa, respectively, over a 1-year period), and their data were compared. RESULTS: No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial @entity409 . The observed @entity409 improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial @entity409 was higher in the @entity409 improvement group (n=63) than in the @entity409 deterioration group (n=33; 7.9 vs. 4.8 kPa, P<0.001). However, there were no differences in any other clinical characteristic. In the antiviral therapy (-) group, the initial @entity409 was also higher in the @entity409 improvement group (n=29) than in the @entity409 deterioration group (n=26; 8.3 vs. 6.5 kPa, P=0.021), with no differences in any other clinical characteristic. CONCLUSIONS: A higher initial @entity409 was the only factor associated with @entity409 improvement in @entity1 with @entity6194 in this study.
